CA2909669A1 - Activite antivirale de l'inhibiteur gas6 - Google Patents

Activite antivirale de l'inhibiteur gas6 Download PDF

Info

Publication number
CA2909669A1
CA2909669A1 CA2909669A CA2909669A CA2909669A1 CA 2909669 A1 CA2909669 A1 CA 2909669A1 CA 2909669 A CA2909669 A CA 2909669A CA 2909669 A CA2909669 A CA 2909669A CA 2909669 A1 CA2909669 A1 CA 2909669A1
Authority
CA
Canada
Prior art keywords
axl
mer
polypeptide
tyro3
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2909669A
Other languages
English (en)
Other versions
CA2909669C (fr
Inventor
Raymond Tabibiazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aravive Biologics Inc
Original Assignee
Ruga Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruga Corp filed Critical Ruga Corp
Publication of CA2909669A1 publication Critical patent/CA2909669A1/fr
Application granted granted Critical
Publication of CA2909669C publication Critical patent/CA2909669C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Des compositions et méthodes sont prévues pour traiter l'infection virale chez un mammifère en administrant une dose thérapeutique d'une composition pharmaceutique inhibant l'activité protéique AXL, MER ou Tyro3, par exemple par inhibition de l'interaction de liaison entre AXL, MER ou Tyro3 et son ligand GAS6.
CA2909669A 2014-10-20 2015-10-20 Activite antivirale de l'inhibiteur gas6 Active CA2909669C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066223P 2014-10-20 2014-10-20
US62/066,223 2014-10-20

Publications (2)

Publication Number Publication Date
CA2909669A1 true CA2909669A1 (fr) 2016-04-20
CA2909669C CA2909669C (fr) 2023-12-12

Family

ID=55756054

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909669A Active CA2909669C (fr) 2014-10-20 2015-10-20 Activite antivirale de l'inhibiteur gas6

Country Status (2)

Country Link
US (1) US10137173B2 (fr)
CA (1) CA2909669C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352404B2 (en) 2017-07-24 2022-06-07 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484628B (zh) * 2019-07-31 2022-06-14 扬州大学 一种金茅黑鸡腹脂性状相关的分子标记与应用
AU2021252094A1 (en) * 2020-04-08 2022-11-10 Bergenbio Asa AXL inhibitors for antiviral therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
CA2175893C (fr) 1993-11-23 2010-06-22 Paul J. Godowski Tyrosine kinases proteiques appelees rse
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030032102A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2003068983A1 (fr) 2002-02-12 2003-08-21 Quark Biotech, Inc. Utilisation du recepteur axl pour le diagnostic et le traitement d'une maladie renale
EP1382969A1 (fr) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnostic et traitement de l'invasion des cellules cancéreuses
WO2004108748A2 (fr) 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Peptides du gene 6 specifique de l'arret de croissance, anticorps, compositions, procedes et utilisations associes
AU2004231036A1 (en) 2003-04-18 2004-10-28 Novartis Ag Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
EP1825005B1 (fr) 2004-11-24 2015-07-15 The Regents of the University of Colorado, a body corporate Agents diagnostiques et therapeutiques a base de mer
EP1897940A4 (fr) 2005-05-02 2009-04-15 Toray Industries Composition et procédé permettant de diagnostiquer un cancer oesophagien et une métastase d'un cancer oesophagien
RS53281B (en) 2006-12-29 2014-08-29 Rigel Pharmaceuticals Inc. POLYCYCLIC HETEROaryl SUBSTITUTED TRIAZOLES USED AS AXL INHIBITORS
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
EP2170395A1 (fr) 2007-07-02 2010-04-07 Wyeth LLC Modulateurs de axl pour le traitement de troubles osseux
JP2011514881A (ja) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
WO2011091305A2 (fr) 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la signalisation axl dans une thérapie antimétastasique
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
JP5940061B2 (ja) 2010-06-18 2016-06-29 ジェネンテック， インコーポレイテッド 抗ａｘｌ抗体及び使用方法
WO2013090776A1 (fr) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la signalisation axl/gas6 dans le traitement d'une maladie
DK2931265T6 (da) 2012-12-14 2023-05-01 Univ Leland Stanford Junior Modificerede AXL-petider og deres anvendelse til inhibering af AXL-signalering i en antimetastatisk terapi
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352404B2 (en) 2017-07-24 2022-06-07 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use

Also Published As

Publication number Publication date
US10137173B2 (en) 2018-11-27
CA2909669C (fr) 2023-12-12
US20160206705A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
TWI328456B (en) Binding agents which inhibit myostatin
DK2443137T3 (en) NOVEL chemokine-binding peptides capable of impeding the sequence for immunity, inflammation and cancer
AU2019210662B2 (en) Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
CA2909669C (fr) Activite antivirale de l'inhibiteur gas6
JP7428404B2 (ja) Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置
CA2971406A1 (fr) Activite antifibrotique d'inhibiteur de gas6
MXPA06003695A (es) Usos terapeuticos de variantes de quimiocinas.
US11560412B2 (en) Compositions comprising GRIM-19 therapeutics and methods of use
JP2005511015A (ja) 神経再生ペプチドおよび脳損傷治療におけるその使用方法
CA2671410C (fr) Peptide et traitement pour une infection par le hiv-1
Zhang et al. A conserved domain of herpes simplex virus ICP34. 5 regulates protein phosphatase complex in mammalian cells
US9737588B2 (en) Method for treating arthritis using IK factor or nucleic acid encoding IK factor
Nobusawa et al. The role of acidic residues in the “fusion segment” of influenza A virus hemagglutinin in low-pH-dependent membrane fusion
US11174322B2 (en) Antibodies and peptides to treat HCMV related diseases
EP4046653A1 (fr) Polypeptides immunogènes et leurs utilisations
US7186408B2 (en) Viral CD30 polypeptide
CA3235565A1 (fr) Proteines tronquees et de fusion
KR20220139079A (ko) 세포 투과성 펩타이드 변이체 및 이의 용도
WO2022013304A1 (fr) POLYPEPTIDES PDGFRα EN TANT QUE RÉCEPTEURS LEURRES VIRAUX
Totonchy et al. Cytomegalovirus CC Chemokine Promotes Immune Cell Migration
WO2008097854A2 (fr) Procédé et substances pour traiter une infection par le vph

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826

EEER Examination request

Effective date: 20200826